CAS
TAK icon

Coppell Advisory Solutions’s Takeda Pharmaceutical TAK Stock Holding History

Coppell Advisory Solutions’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$62 – 1861
2023
Q3 		$62 Buy
+4
New +$62 ﹤0.01% 1164

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Coppell Advisory Solutions's TAK Position: Q4 2023 in Review

Coppell Advisory Solutions sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 4 shares — an estimated $62 sold.

Coppell Advisory Solutions first reported a position in TAK in Q3 2023 and held it in 1 quarter. The position peaked at $62 in Q3 2023. 306 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

  • Coppell Advisory Solutions reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
  • Coppell Advisory Solutions sold 4 Takeda Pharmaceutical shares in Q4 2023, an estimated $62.
  • Coppell Advisory Solutions first reported a position in Takeda Pharmaceutical in Q3 2023 and held it in 1 quarter.
  • Coppell Advisory Solutions's Takeda Pharmaceutical position peaked at $62 in Q3 2023.
  • 306 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.